@article{ref1,
title="Lantus overdose: case presentation and management options",
journal="Journal of emergency medicine",
year="2009",
author="Fuller, Everett T. and Miller, Michael A. and Kaylor, David W. and Janke, Cliff",
volume="36",
number="1",
pages="26-29",
abstract="Insulin glargine (Lantus, Aventis Pharmaceuticals, Bridgewater, NJ) is a long-acting once-daily dosed form of insulin intended to maintain a constant baseline insulin level. As a relatively new medication, there is limited experience in overdoses of Lantus. We present a case of a 37-year-old male insulin-dependent diabetic presenting with refractory hypoglycemia secondary to an intentional overdose of Lantus insulin to illustrate the varied management concerns in overdoses of long-acting insulins. The patient was managed with oral intake, intravenous dextrose bolus, peripheral 10% dextrose solution, 25% dextrose sliding scale via central line, and psychiatry evaluation for suicide attempt. Other potential treatments discussed for possible use with long-acting insulin overdoses include incision and drainage of the injection site, glucagon, and octreotide.<p /><p>Language: en</p>",
language="en",
issn="0736-4679",
doi="10.1016/j.jemermed.2007.02.038",
url="http://dx.doi.org/10.1016/j.jemermed.2007.02.038"
}